Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes? Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Immunotherapy
  • Indoles
  • Melanoma
  • Sulfonamides

abstract

  • © 2019 Elsevier Inc. It has been widely assumed that PD-1 blockade works by reinvigorating (“rebooting”) pre-existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-therapy.

publication date

  • September 16, 2019

Research

keywords

  • Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2019.08.009

Additional Document Info

start page

  • 215

end page

  • 217

volume

  • 36

number

  • 3